Beijing Tong Ren Tang Chinese Medicine Co Ltd (HK:3613)
:3613
Want to see HK:3613 full AI Analyst Report?
Top Page
Beijing Tong Ren Tang Chinese Medicine Co
(3613)
Select Model
Select Model
Rating:68Neutral
Price Target:
HK$8.00
▼(-7.08% Downside)
Action:Reiterated
Date:05/02/26
The score is supported primarily by strong financial quality (high profitability and very low leverage), and a reasonable valuation with an attractive dividend yield. These positives are tempered by weak technical signals (price below key moving averages with negative MACD) and recent fundamental softening (2025 revenue decline and reduced ROE with prior-year cash-flow volatility).
Positive Factors
Very low leverage
An exceptionally low debt-to-equity (~0.03) gives durable financial flexibility. Over the next 2–6 months this supports capital allocation optionality—funding store investment, product rollouts, dividends or opportunistic M&A—while limiting refinancing and interest-rate stress.
Negative Factors
Revenue decline
An 11.4% revenue drop in 2025 signals weakening demand or pricing/mix pressure. If top-line weakness persists, it can erode operating leverage and force margin tradeoffs, reducing capacity to invest in stores, product development or marketing over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
An exceptionally low debt-to-equity (~0.03) gives durable financial flexibility. Over the next 2–6 months this supports capital allocation optionality—funding store investment, product rollouts, dividends or opportunistic M&A—while limiting refinancing and interest-rate stress.
Read all positive factors
Beijing Tong Ren Tang Chinese Medicine Co (3613) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$5.94B
Dividend Yield4.04%
Average Volume (3M)1.10M
Price to Earnings (P/E)17.8
Beta (1Y)0.69
Revenue Growth-6.10%
EPS Growth-20.60%
CountryHK
Employees782
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)0.38
Shares Outstanding837,100,000
10 Day Avg. Volume975,850
30 Day Avg. Volume1,095,238
Financial Highlights & Ratios
PEG Ratio-0.82
Price to Book (P/B)1.69
Price to Sales (P/S)4.68
P/FCF Ratio8.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$10.50Price Target Upside21.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.65
Revenue Forecast (FY)HK$1.81B
Beijing Tong Ren Tang Chinese Medicine Co Business Overview & Revenue Model
Company Description
Beijing Tong Ren Tang Chinese Medicine Company Limited, together with its subsidiaries, engages in the manufacture, retail, and wholesale of Chinese medicine and healthcare products to wholesalers and individuals. The company operates through thre...
How the Company Makes Money
The company makes money primarily by selling TCM products through multiple channels. (1) Manufacturing and product sales: It generates revenue from producing and selling Chinese patent medicines and other TCM products, earning gross profit on the ...
Beijing Tong Ren Tang Chinese Medicine Co Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
90
Very Positive
Cash Flow
70
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.51B | 1.61B | 1.52B | 1.73B | 1.56B |
| Gross Profit | 925.58M | 1.07B | 1.05B | 1.15B | 1.12B |
| EBITDA | 495.52M | 722.32M | 779.54M | 907.63M | 852.81M |
| Net Income | 397.22M | 500.28M | 540.39M | 645.88M | 607.84M |
Balance Sheet | |||||
| Total Assets | 4.66B | 4.56B | 4.43B | 4.23B | 3.83B |
| Cash, Cash Equivalents and Short-Term Investments | 2.28B | 1.82B | 2.38B | 2.24B | 2.28B |
| Total Debt | 126.54M | 123.42M | 131.81M | 103.08M | 128.48M |
| Total Liabilities | 291.88M | 313.09M | 413.75M | 486.49M | 295.48M |
| Stockholders Equity | 4.19B | 4.08B | 3.87B | 3.60B | 3.42B |
Cash Flow | |||||
| Free Cash Flow | 827.05M | -260.42M | 438.96M | 508.94M | 753.74M |
| Operating Cash Flow | 868.23M | -217.25M | 460.83M | 547.44M | 777.17M |
| Investing Cash Flow | -37.73M | 1.35B | -1.08B | 335.41M | -265.73M |
| Financing Cash Flow | -381.05M | -355.30M | -372.18M | -535.42M | -278.65M |
Beijing Tong Ren Tang Chinese Medicine Co Technical Analysis
Negative
8.61
Price Trends
7.71
Negative
8.19
Negative
8.59
Negative
Market Momentum
-0.14
Positive
32.27
Neutral
8.75
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3613, the sentiment is Negative. The current price of 8.61 is above the 20-day moving average (MA) of 7.34, above the 50-day MA of 7.71, and above the 200-day MA of 8.59, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 32.27 is Neutral, neither overbought nor oversold. The STOCH value of 8.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3613.
Beijing Tong Ren Tang Chinese Medicine Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | HK$6.24B | 17.47 | 15.51% | 2.61% | 7.60% | 20.01% | |
68 Neutral | HK$5.94B | 17.83 | 12.72% | 4.04% | -6.10% | -20.60% | |
60 Neutral | HK$4.66B | 12.80 | 5.98% | 4.47% | -10.79% | -24.52% | |
58 Neutral | HK$1.99B | -22.90 | -2.70% | ― | -32.11% | -229.14% | |
58 Neutral | HK$9.36B | 11.74 | 5.02% | 4.47% | 5.91% | -40.12% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$8.11B | -27.64 | -1.66% | 3.66% | -10.68% | -737.07% |
* Healthcare Sector Average
HK:3613
Beijing Tong Ren Tang Chinese Medicine Co
7.14
-1.20
-14.35%
HK:0570
China Traditional Chinese Medicine Holdings Co
1.60
-0.50
-23.66%
HK:1666
Tong Ren Tang Technologies Co
3.67
-1.21
-24.84%
HK:1643
Modern Chinese Medicine Group Co. Ltd.
2.80
2.42
636.84%
HK:2273
Gushengtang Holdings Limited
26.84
-6.35
-19.13%
HK:0719
Shandong Xinhua Pharmaceutical Company Limited Class H
6.25
0.59
10.42%
Beijing Tong Ren Tang Chinese Medicine Co Corporate Events
Beijing Tong Ren Tang Chinese Medicine Sets 2026 AGM, Proposes Dividends and Share Issue Mandate
Apr 29, 2026
Beijing Tong Ren Tang Chinese Medicine Company Limited has called its annual general meeting for 10 June 2026 in Hong Kong, where shareholders will vote on adopting the 2025 audited financial statements and related reports, and on the re-election ...
Beijing Tong Ren Tang Chinese Medicine Flags Q1 2026 Results Releases by Parent Companies
Apr 27, 2026
Beijing Tong Ren Tang Chinese Medicine Company Limited has informed investors that its controlling shareholder, Tong Ren Tang Technologies Co. Ltd., has released unaudited consolidated financial information for the first quarter ended 31 March 202...
Beijing Tong Ren Tang Chinese Medicine Wins Macau Approval for New Remedy
Apr 20, 2026
Beijing Tong Ren Tang Chinese Medicine Company’s Macau subsidiary has received a Certificate of Registration of Proprietary Chinese Medicine from the Pharmaceutical Administration Bureau of the Macao SAR, authorizing the sale of its Jin Chai...
Beijing Tong Ren Tang Chinese Medicine Declares Special Dividend for 2025
Mar 20, 2026
Beijing Tong Ren Tang Chinese Medicine Company Limited has declared a special cash dividend of HKD 0.03 per share for the financial year ended 31 December 2025, following shareholder approval on 10 March 2026. The special dividend will be paid in ...
Beijing Tong Ren Tang Chinese Medicine Profit Falls but Dividends Raised on Strong Cash Position
Mar 20, 2026
Beijing Tong Ren Tang Chinese Medicine reported weaker 2025 results, with revenue down 6.1% to HK$1.51 billion and profit attributable to shareholders sliding 20.6% to HK$397.2 million, as gross profit contracted and impairment losses on financial...
Beijing Tong Ren Tang Chinese Medicine Sets HKD 0.37 Final Dividend for 2025
Mar 20, 2026
Beijing Tong Ren Tang Chinese Medicine Company Limited has proposed a final ordinary cash dividend of HKD 0.37 per share for the financial year ended 31 December 2025, highlighting its intention to return profits to shareholders. The dividend is s...
Beijing Tong Ren Tang Chinese Medicine Sets March Board Meeting on 2025 Results and Dividend
Mar 6, 2026
Beijing Tong Ren Tang Chinese Medicine Company Limited has scheduled a board meeting for 20 March 2026 to review and approve the annual results of the company and its subsidiaries for the financial year ended 31 December 2025. The board will also ...
Beijing Tong Ren Tang Chinese Medicine Wins Shareholder Backing for Renewed PRC Distribution Deal
Feb 11, 2026
Beijing Tong Ren Tang Chinese Medicine Company Limited has secured shareholder approval at an extraordinary general meeting held in Hong Kong on 11 February 2026, where all proposed ordinary resolutions were passed by poll. The meeting, attended b...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.